Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Nevro Corp. ("Nevro" or the "Company") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the "SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2023, the Company announced that Mr. D. Keith Grossman has informed the Board of Directors of the Company of his intention to retire as the Company's Chief Executive Officer and President in 2023 following the selection of his successor. Mr. Grossman will remain in his role as Chairman of the Board.

Item 9.01 Financial Statements and Exhibits.



Exhibit No.   Description

99.1            Press release dated January 9, 2023  .

104           Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses